Andrew MacGinnitie

Andrew MacGinnitie, MD, PhD

Associate Clinical Director, Division of Immunology

Assistant Professor of Pediatrics

    Contact: 617-355-6117
  • Fax: 617-730-0310

Medical Services

Specialties

  • Food Allergy
  • Asthma
  • Hereditary Angioedema
  • Allergic Rhinitis
  • Urticaria
  • Drug Allergy
  • Immunodeficiency
  • Eczema
  • Recurrent Infections

Departments

  • Allergy Immunology

Programs

  • Allergy Program
  • Primary Immunodeficiency Disorders Program
To schedule an appointment: Call 617-355-6117 or Request an Appointment

Experience and Education

Education

Psychology

Yale University,

New Haven, CT

Medicine

University of Chicago, Pritzker School of Medicine,

Chicago, IL

Ph.D.

University of Chicago, 1996

Chicago, IL

Allergy Immunology

Boston Children's Hospital , 2001-2004

Boston, Ma

Pediatrics

Boston Combined Residency Program, 1998-1999

Boston, Ma

Pediatrics

Boston Combined Residency Program, 1999-2004

Boston, Ma

Certifications

  • Allergy/Immunology, Pediatrics

Publications

Publications powered by Harvard Catalyst Profiles
  1. MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, Heimall J, Makhija M, Robison R, Chinthrajah RS, Lee J, Lebovidge J, Dominguez T, Rooney C, Lewis MO, Koss J, Burke-Roberts E, Chin K, Logvinenko T, Pongracic JA, Umetsu DT, Spergel J, Nadeau KC, Schneider LC. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2016 Sep 5.
  2. Levy S, Dedeoglu F, Gaffin JM, Garvey KC, Harstad E, MacGinnitie A, Rufo PA, Huang Q, Ziemnik RE, Wisk LE, Weitzman ER. A Screening Tool for Assessing Alcohol Use Risk among Medically Vulnerable Youth. PLoS One. 2016; 11(5):e0156240.
  3. Craig TJ, Schneider LC, MacGinnitie AJ. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review. Pediatr Allergy Immunol. 2015 Sep; 26(6):537-44.
  4. Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015 Mar-Apr; 3(2):206-212.e4.
  5. MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014 Aug; 25(5):420-7.
  6. MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. Pediatrics. 2013 Aug; 132(2):e490-7.
  7. Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc. 2013 Mar-Apr; 34(2):155-61.
  8. Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):168-72.
  9. Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):184-188.e2.
  10. Jacobs TS, Jones BL, MacGinnitie AJ. Long-acting beta-agonists and the risk of intensive care unit admission in children. J Asthma. 2012 Jun; 49(5):450-5.
  11. Show all
  12. MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. Allergy Asthma Proc. 2012 Mar-Apr; 33(2):178-85.
  13. Ruffner MA, Finegold DN, MacGinnitie AJ. Infant with unusual food reactions. Acta Paediatr. 2011 Oct; 100(10):1289, 1394-5.
  14. McHugh BM, MacGinnitie AJ. Indoor allergen sensitization and the risk of asthma and eczema in children in Pittsburgh. Allergy Asthma Proc. 2011 Sep-Oct; 32(5):372-6.
  15. Burke S, Petrov A, Johnson J, MacGinnitie A. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis. Ann Allergy Asthma Immunol. 2011 Aug; 107(2):181-2.
  16. MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol. 2011 Nov; 22(7):671-5.
  17. Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol. 2011 Jan; 127(1):264-5.
  18. MacGinnitie A. In utero anaphylaxis. Med Hypotheses. 2011 Jan; 76(1):70-2.
  19. Puglisi G, Netravali MA, MacGinnitie AJ, Bonagura VR. 11q terminal deletion disorder and common variable immunodeficiency. Ann Allergy Asthma Immunol. 2009 Sep; 103(3):267-8.
  20. Scholnicoff ET, MacGinnitie AJ, Lin PL, Darville T. Chronic granulomatous disease in an adolescent with recurrent impetigo and cholecystectomy. Pediatr Infect Dis J. 2009 Mar; 28(3):255-7.
  21. Kapadia SB, Macginnitie AJ, Shaw PH. X-linked lymphoproliferative disease in an EBV-negative patient presenting with pancytopenia. Pediatr Blood Cancer. 2008 Jun; 50(6):1296-7.
  22. MacGinnitie AJ, Walensky LD, Turvey SE, Orange JS, Bonilla FA, Silverman LB, Oettgen H. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol. 2003 Oct; 14(5):409-11.
  23. MacGinnitie AJ, Geha R. X-linked lymphoproliferative disease: genetic lesions and clinical consequences. Curr Allergy Asthma Rep. 2002 Sep; 2(5):361-7.
  24. Anant S, Martin SA, Yu H, MacGinnitie AJ, Devaney E, Davidson NO. A cytidine deaminase expressed in the post-infective L3 stage of the filarial nematode, Brugia pahangi, has a novel RNA-binding activity. Mol Biochem Parasitol. 1997 Sep; 88(1-2):105-14.
  25. Davidson NO, Anant S, MacGinnitie AJ. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr Opin Lipidol. 1995 Apr; 6(2):70-4.
  26. MacGinnitie AJ, Anant S, Davidson NO. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J Biol Chem. 1995 Jun 16; 270(24):14768-75.
  27. Madsen P, Anant S, Rasmussen HH, Gromov P, Vorum H, Dumanski JP, Tommerup N, Collins JE, Wright CL, Dunham I, MacGinnitie AJ, Davidson NO, Celis JE. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J Invest Dermatol. 1999 Aug; 113(2):162-9.
  28. Anant S, MacGinnitie AJ, Davidson NO. apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem. 1995 Jun 16; 270(24):14762-7.
  29. Anant S, MacGinnitie AJ, Davidson NO. The binding of apobec-1 to mammalian apo B RNA is stabilized by the presence of complementation factors which are required for post-transcriptional editing. Nucleic Acids Symp Ser. 1995; (33):99-102.
  30. He R, Kim HY, Yoon J, Oyoshi MK, MacGinnitie A, Goya S, Freyschmidt EJ, Bryce P, McKenzie AN, Umetsu DT, Oettgen HC, Geha RS. Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13. J Allergy Clin Immunol. 2009 Oct; 124(4):761-70.e1.
To schedule an appointment: Call 617-355-6117 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close